Physician profile
Ronald Harmon
NPI 1215403712
$7,054.99
in general payments reported to CMS, 2019-2025
30 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,725 · 2022: $1,255 · 2023: $1,228 · 2024: $1,626 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.46 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,696.14 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,463.30 | 2021-2025 | Relistor |
| Abbvie INC. | $922.12 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $530.79 | 2021-2025 | Ztlido |
| Medtronic, INC. | $431.55 | 2024 | Synchromedii, Intellis Adaptivestim |
| Boston Scientific Corporation | $360.39 | 2022-2025 | Patient Trial Kit, Intracept, Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $293.03 | 2021 | |
| Protega Pharmaceutials INC | $164.98 | 2022-2024 | Roxybond |
| Daiichi Sankyo INC. | $125.00 | 2021 | |
| Amgen INC. | $118.14 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.67 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $101.78 | 2022 | |
| Lundbeck LLC | $85.04 | 2022-2025 | Vyepti |
| Redhill Biopharma INC. | $84.32 | 2021-2022 | |
| Tonix Medicines, INC. | $84.05 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $81.85 | 2021 | |
| Averitas Pharma INC. | $63.26 | 2023-2025 | Qutenza |
| Nevro Corp. | $49.66 | 2022-2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $41.14 | 2024-2025 | |
| Globus Medical, INC. | $39.82 | 2025 | Senza |
| Stimwave Technologies Incorporated | $31.28 | 2022 | |
| Relievant Medsystems, INC. | $30.01 | 2023 | Intracept |
| Pacira Pharmaceuticals Incorporated | $24.79 | 2023 | Zilretta, Iovera |
| Painteq LLC | $23.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.50 | 2024 | Givlaari |
| Lilly USA, LLC | $18.06 | 2023 | Emgality |
| Biodelivery Sciences International, INC. | $17.02 | 2021 | |
| Grt US Holding, INC. | $16.53 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.94 | 2023 | Lyvispah |
| Allergan, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.